PALO ALTO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will participate in a fireside chat at the Bank of America Merrill Lynch Global Healthcare Conference 2025 in Las Vegas, NV on Wednesday, May 14 at 2:20 pm PT. To access the live webcast of BridgeBio’s presentation, please visit the “Events” page within the Investors s ...

BridgeBio Pharma (BBIO) Q1 2025 Earnings Call April 29, 2025 09:37 PM ET Speaker0 Afternoon. I will be your conference operator today. All lines have been placed on mute to prevent any background noise. After the company's remarks, there will be a question and answer session. Thank you. Before we begin, I would like to remind everyone that today's call may contain forward looking statements within the meaning of the federal securities laws, including, but not limited to, statements about BridgeBio's future ...

Financial Performance - BridgeBio Pharma reported a quarterly loss of $0.88 per share, which was better than the Zacks Consensus Estimate of a loss of $1, representing an earnings surprise of 12% [1] - The company posted revenues of $116.63 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 86.76%, although this is a decline from year-ago revenues of $211.12 million [2] - Over the last four quarters, BridgeBio Pharma has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - Since the beginning of the year, BridgeBio Pharma shares have increased by approximately 30.8%, contrasting with a decline of 6% in the S&P 500 [3] - The stock's immediate price movement will largely depend on management's commentary during the earnings call [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.98 on revenues of $60.98 million, and for the current fiscal year, it is -$4.18 on revenues of $255.08 million [7] - The estimate revisions trend for BridgeBio Pharma is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Generic Drugs industry, to which BridgeBio Pharma belongs, is currently ranked in the top 29% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38959 BridgeBio Pharma, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporati ...

BridgeBio Pharma (BBIO) Q1 2025 Earnings Call April 29, 2025 04:30 PM ET Company Participants Chinmay Shukla - VP - Strategic FinanceNeil Kumar - Co-Founder, CEO & DirectorMatthew Outten - Chief Commercial OfficerThomas Trimarchi - President & CFOSalim Syed - Managing Director, Equity ResearchMani Foroohar - Senior Managing DirectorCory Kasimov - Senior Managing DirectorGreg Harrison - Director - BiotechnologyAnanth Sridhar - COO - CardiorenalJason Zemansky - Vice President, Equity Research, Biotechnology a ...

Exhibit 99.1 BridgeBio Reports First Quarter 2025 Financial Results and Business Updates - $36.7 million in first full quarter of U.S. Attruby™ net product revenue and as of April 25, 2025, 2,072 unique patient prescriptions written by 756 unique prescribers - Observational run-in study for hypochondroplasia Phase 2 trial fully enrolled significantly ahead of schedule. The first participant was also dosed in the Phase 2 interventional study - Proof-of-principle study of encaleret, an oral calcium-sensing re ...

- $36.7 million in first full quarter of U.S. Attruby™ net product revenue and as of April 25, 2025, 2,072 unique patient prescriptions written by 756 unique prescribers - Observational run-in study for hypochondroplasia Phase 2 trial fully enrolled significantly ahead of schedule. The first participant was also dosed in the Phase 2 interventional study - Proof-of-principle study of encaleret, an oral calcium-sensing receptor antagonist, in hypoparathyroidism resulted in 78% of N=9 study participants achie ...

- A 50% reduction in the cumulative frequency of CVH events relative to placebo at Month 30 - Acoramidis is the first and only approved ATTR-CM treatment in the U.S., EU, UK and Japan that all have a label specifying near-complete stabilization (≥90%) - The UK approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date - In as few as 3 months, the time to first event (all-cause mortality (ACM) ...

NEW YORK, April 23, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating BridgeBio Pharma, Inc. (NASDAQ: BBIO) on behalf of the company's shareholders.  The investigation seeks to determine whether BridgeBio Pharma's directors breached their fiduciary duties in connection with recent corporate actions.If you are a shareholder of BridgeBio Pharma and are interested in obtaining additional information regarding your rights and options, free of charge, please visit us at: https://pjl ...

PALO ALTO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that it will release its first quarter financial results and program updates after the market closes on Tuesday, April 29, 2025. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webcast of BridgeBio's presentation, ...